Welcome Christopher Rumana, MD, and Johana Vega Leonel, PhD, to our Medical & Scientific Advisory Board! Their expertise in neurosurgery, neuroengineering and healthcare innovation will help advance TEMT-RF from research to real-world impact.

Alzheimer's can seem like a fate worse than death, but a wave of innovation is bringing new hope to the 7 million Americans living with the disease. Read more from our CEO on the emerging non-drug therapies like our TEMT-RF in Medical Device News.

Join millions who have switched to Grok.

Introducing…Sam Alex Mulder, our Chief of Staff & Operations Manager, whose detail-orientation, strategic thinking, and get-it-done energy will help scale our internal infrastructure while ensuring smooth execution across programs, studies & milestones.

Emerging non-drug Alzheimer's therapies using novel techniques like electrical stimulation, light therapy & radio waves also promise to safely stop cognitive decline, inc. our TEMT-RF, which early clinical trials suggest can reverse damage. @AllysiaFinley

Introducing … Our CFO, Marilyn Thompson. Her exceptional talents in GAAP, financial accounting, and strategic planning ensure NeuroEM has the solid financial footing we need as we focus on commercializing our TEMT-RF technology.

The FDA has cleared the first blood test to help diagnose Alzheimer’s, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. It detects amyloid plaques in adults 55+. Early studies have shown these plaques are gently broken up by our TEMT-RF.

Our origin story starts with an unexpected discovery. Researchers expecting to find that prolonged exposure to electromagnetic waves speeds cognitive decline instead found that TEMT-RF exposure prevented and reversed it in mice with Alzheimer’s |

A new study in @jnutritionorg found that eating 1 egg a week was associated with a 47% reduction in Alzheimer’s risk and that those who ate eggs had a reduced buildup of toxic proteins associated with the disease, proteins our TEMT-RF targets.

Introducing…Amanda Patanow, Chief Product & Marketing Officer. A problem-solver, plan designer & doer of the impossible, Amanda operates at the intersection of strategy, storytelling & science, a talent she brings to commercializing our TEMT-RF tech |

Introducing…Tracy Ingram, NeuroEM’s COO/CIO. A 2025 Tampa Titan 100, he's an experienced medical device technologist who co-founded Healthcamp Florida, focused on identifying innovative medical technologies – like our TEMT-RF to enhance brain health |

A new study found that people who follow the MIND diet, which combines the Mediterranean diet with the blood pressure-lowering DASH diet and emphasizes proven brain-healthy foods, were less likely to develop Alzheimer’s or related forms of dementia |

NeuroEM was the first to receive Breakthrough Device status from the FDA to treat Alzheimer’s disease. Learn what that means here:

Introducing…Our weekly series introducing the NeuroEM team! First up is CEO Chuck Papageorgiou. Described as a force of nature who’s unafraid to roll up his sleeves and make the hard decisions, Chuck is passionate about commercializing our TEMF-TE |

In Neuron, new research has uncovered how Alzheimer's-related changes can spread across multiple tissues, which could lead to the discovery of new diagnostic markers and more effective treatment strategies for Alzheimer’s. Read more in SciTechDaily:

Tracy Ingram "is a formidable force in the Tampa Bay tech ecosystem, making a significant impact through his diverse and influential contributions." We agree! Congratulations to NeuroEM COO/CIO @tracyingram for his recognition as a 2024 Tampa Titan 100 |

Our own Amanda Patanow shared with The Big Idea CONNECTpreneur Networking & Pitch Extravaganza the story behind NeuroEM and its pioneering TEMF-TE technology, and why they represent hope for those with Alzheimer’s and other neurodegenerative conditions |

Neuro Rehab Times sat down with CEO Chuck Papageorgiou to talk about the state of Alzheimer’s care, the desperate need for innovative therapies, and how our groundbreaking TEMT-TF tech may bring hope to those living with this devastating diagnosis |

In NeuroEM news, we closed the initial $1.3 million of a $5 million equity raise with to advance commercialization of our TEMT-RF tech to treat cognitive decline caused by aging or Alzheimer's and other neurodegenerative diseases |

RT @NPC_Creative: Congratulations to NeuroEM for its @TampaBayInno Healthtech award! Its radio wave-based treatment for Alzheimer’s is a sa….

RT @jaymohan: Innovating #Alzheimers Treatment! NeuroEM Therapeutics is using Transcranial Electromagnetic Treatment with Radio Frequencie….